Photo from wikipedia
Anti-tumor necrosis factor alpha (TNFα) therapies are used with success in many chronic inflammatory diseases. A wide range of adverse events has been reported in patients receiving these agents1, including… Click to show full abstract
Anti-tumor necrosis factor alpha (TNFα) therapies are used with success in many chronic inflammatory diseases. A wide range of adverse events has been reported in patients receiving these agents1, including lichenoid eruptions, lupus-like syndrome1, 2 and psoriasiform eruptions3. Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus (CLE), which occurs approximately in 1%-3% of CLE. Here we report a case of a patient with rheumatoid arthritis (RA) treated with anti-TNFα that developed skin lesions clinically and pathologically compatible with LEP. This article is protected by copyright. All rights reserved.
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!